Mohamed Elmeliegy
Pfizer (United States)(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Multiple Myeloma Research and Treatments, PARP inhibition in cancer therapy, Renal and related cancers, Glioma Diagnosis and Treatment
Most-Cited Works
- → Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer(2018)845 cited
- → Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results(2023)511 cited
- → Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies(2020)303 cited
- → Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation(2010)110 cited
- → Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial(2019)83 cited
- → Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer(2016)80 cited
- → Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations(2017)78 cited
- → Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas(2010)71 cited
- → Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma(2018)56 cited